With appropriate patient selection, monitoring, and medical supervision, weight loss injections can be used safely in most individuals, including many with cardiovascular risk factors or established heart disease
In clinical trials, the daily pill produced an average weight loss of up to 13%
This is why the 4-week minimum at each dose level exists
The rationale is straightforward: a 120kg individual has significantly more tissue volume for the peptide to distribute through than a 70kg individual, which affects both the effective concentration at receptor sites and the perceived intensity of side effects
The most important initial strategy is adherence to the prescribed dose escalation schedule
As these cases unfold, they serve as a poignant reminder of the need for vigilance in pharmaceutical oversight and the importance of informed consent in medical treatment